pcDNA3-sACE2v2.4(732)-IgG1 Citations (3)

Originally described in: Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E Science. 2020 Sep 4;369(6508):1261-1265. doi: 10.1126/science.abc0870. Epub 2020 Aug 4. PubMed Journal

---

Articles Citing pcDNA3-sACE2v2.4(732)-IgG1

Articles
Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity. Havranek B, Chan KK, Wu A, Procko E, Islam SM. J Chem Inf Model. 2021 Sep 27;61(9):4656-4669. doi: 10.1021/acs.jcim.1c00783. Epub 2021 Aug 24. PubMed
Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. Wang Q, Nair MS, Anang S, Zhang S, Nguyen H, Huang Y, Liu L, Ho DD, Sodroski JG. iScience. 2021 Nov 19;24(11):103393. doi: 10.1016/j.isci.2021.103393. Epub 2021 Nov 1. PubMed
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. Zhang L, Narayanan KK, Cooper L, Chan KK, Devlin CA, Aguhob A, Shirley K, Rong L, Rehman J, Malik AB, Procko E. bioRxiv. 2022 Mar 28. doi: 10.1101/2022.03.28.486075. PubMed

If you have published an article using this material, please email us at to have your article added to this page.